The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma
Abstract
PURPOSE: Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin’s lymphoma (NHL). Ibritumomab tiuxetan radioimmunotherapy targets the same antigen as rituximab and has demonstrated efficacy in rituximab-naïve NHL. This study evaluated ibritumomab tiuxetan in the treatment of rituximab-refractory follicular NHL. PATIENTS AND METHODS: Eligible patients were refractory to rituximab; this was defined as no objective response to rituximab (375 mg/m 2 weekly for 4 weeks) or time to progression (TTP) of ≤ 6 months. The ibritumomab tiuxetan treatment regimen consisted of pretreatment with rituximab (250 mg/m 2 intravenously on days 1 and 8) to deplete peripheral blood B cells, then yttrium-90 ibritumomab tiuxetan (0.4 mCi/kg; maximum, 32 mCi) intravenously on day 8, administered on an outpatient basis. An imaging/dosimetry dose of indium-111 ibritumomab tiuxetan (5 mCi) was injected after rituximab (day 1) in 28 patients. RESULTS: Fifty-seven patients were treated. The median age was 54 years, 74% had tumors ≥ 5 cm, and all were extensively pretreated (median, four prior therapies; range, one to nine). The estimated radiation-absorbed doses to healthy organs were below the study-defined limit in all patients studied with dosimetry. The overall response rate for the 54 patients with follicular NHL was 74% (15% complete responses and 59% partial responses). The Kaplan-Meier–estimated TTP was 6.8 months (range, 1.1 to ≥ 25.9 months) for all patients and 8.7 months for responders. Adverse events were primarily hematologic; the incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 35%, 9%, and 4%, respectively. CONCLUSION: Ibritumomab tiuxetan radioimmunotherapy is effective in rituximab-refractory patients. The only significant toxicity is hematologic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Self-citationWitzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,170
Self-citationCzuczman, M. S., Grillo-López, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., & Varns, C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.268 · Cited by 856
Self-citationDavis, T. A., Grillo-López, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., Maloney, D. G., Weaver, R. L., Rosenberg, J., & Levy, R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3135 · Cited by 687
Self-citationWitzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J., Spies, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3793 · Cited by 539
Self-citationHarris, N. L. (1995) · Current Diagnostic Pathology · doi:10.1016/s0968-6053(00)80051-4 · Cited by 527
Follicular lymphoma: prognostic factors for response and survival.
Gallagher, C. J., Gregory, W. M., Jones, A. E., Stansfeld, A. G., Richards, M. A., Dhaliwal, H. S., Malpas, J. S., & Lister, T. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1470 · Cited by 425
Vose, J. M., Link, B. K., Grossbard, M. L., Czuczman, M., Grillo-Lopez, A., Gilman, P., Lowe, A., Kunkel, L. A., & Fisher, R. I. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.389 · Cited by 417
Self-citationA clinical trial of anti-idiotype therapy for B cell malignancy
Meeker, T., Lowder, J., Maloney, D., Miller, R., Thielemans, K., Warnke, R., & Levy, R. (1985) · Blood · doi:10.1182/blood.v65.6.1349.bloodjournal6561349 · Cited by 416
Johnson, P. W., Rohatiner, A. Z., Whelan, J. S., Price, C. G., Love, S., Lim, J., Matthews, J., Norton, A. J., Amess, J. A., & Lister, T. A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.140 · Cited by 337
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox, S. J., Goris, M. L., Trisler, K. D., Negrin, R. S., Davis, T., Liles, T. M., Grillo-López, A. J., Chinn, P. C., Varns, C., Ning, S., et al. (1996) · PubMed · Cited by 326
Wiseman, G. A., White, C. A., Stabin, M., Dunn, W. L., Erwin, W., Dahlbom, M., Raubitschek, A., Karvelis, K., Schultheiss, T., Witzig, T. E., et al. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590000276 · Cited by 234
Self-citationWiseman, G. A., White, C. A., Sparks, R. B., Erwin, W. D., Podoloff, D. A., Lamonica, D., Bartlett, N. L., Anthony Parker, J., Dunn, W. L., Spies, S. M., et al. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00107-x · Cited by 183
Self-citationSecond cancers following non-Hodgkin's lymphoma
Travis, L. B., Curtis, R. E., Boice, J. D., Hankey, B. F., & Fraumeni, J. F. (1991) · Cancer · doi:10.1002/1097-0142(19910401)67:7<2002::aid-cncr2820670729>3.0.co;2-e · Cited by 178
Ansell, S. M., Witzig, T. E., Kurtin, P. J., et al. (2002) · Blood · doi:10.1182/blood.v99.1.67 · Cited by 148
Self-citationLeukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma.
Travis, L. B., Weeks, J. C., Curtis, R. E., Chaffey, J. T., Stovall, M. A., Banks, P. M., & Boice, J. D. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.565 · Cited by 95
Wiseman, G. A., Leigh, B. R., Erwin, W. D., Lamonica, D. M., Kornmehl, E., SPIES, S. M., Silverman, D. H. S., Witzig, T. E., Sparks, R. B., & White, C. A. (2002) · Cancer · doi:10.1002/cncr.10305 · Cited by 84
Self-citation
Cited by
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Self-citationRadiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 963
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
Radioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3925 · Cited by 537
Metadata
- Authors
- Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S., Saleh, M. N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P. S., & White, C. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-08-01
- Volume
- 20
- Issue
- 15
- Pages
- 3262-3269
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2107990794
- Cited by
- 651
- References
- 22
- FWCI
- 25.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.